
Digital health company Omada Health presented encouraging research results on Tuesday suggesting its diabetes prevention platform — which virtually connects prediabetic patients with health coaches and clinicians — could help curb the symptoms of the disease as well as an equivalent program delivered in person.
The research is in some ways the biggest test yet of a digitally rendered diabetes treatment program ever performed. The study — a randomized controlled trial of nearly 600 people with prediabetes — is larger, longer, and more rigorous than previous studies of similar programs. Omada shared its findings in a presentation during ObesityWeek, a virtual medical conference organized by the Obesity Society; they have yet to be published in a scientific journal.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.